Molecular imaging in pancreatic cancer - A roadmap for therapeutic decisions

Gabriela Kramer-Marek, Jesse Gore, Murray Korc

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Pancreatic ductaladeno carcinoma (PDAC) is a deadly cancer characterized by multiple molecular alterations, the presence of an intense stroma, poor perfusion, and resistance to therapy. In addition to standard imaging techniques, experimental imaging strategies, such as those utilizing molecular probes, nanoparticle-based agents, and tagged antibodies are actively being explored experimentally. It is hoped that advances in these technologies will allow for detecting PDAC at an early stage, and could serve to validate experimental therapies, rapidly identify non-responders, and assist in the design of novel therapeutic strategies tailored to the patient's molecular profile.

Original languageEnglish (US)
Pages (from-to)132-138
Number of pages7
JournalCancer Letters
Issue number2
StatePublished - Dec 1 2013


  • Molecular imaging
  • PDAC
  • Ultrasonography

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Molecular imaging in pancreatic cancer - A roadmap for therapeutic decisions'. Together they form a unique fingerprint.

Cite this